6 recruiting, 3 not yet recruiting, 1 active not recruiting, 1 withdrawn. 5 Phase 2, 4 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Not yet recruiting 2, Active not recruiting 1, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Extensive Stage Small Cell Lung Cancer (ES-SCLC): new trials by email Literature Review of Extensive Stage Small Cell Lung Cancer (ES-SCLC) trials Research Report on Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC HS-20093 for Injection, ZG006, Adebrelimab Injection - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 | Not yet recruiting | Hansoh BioMedical R&D Company | 338 | 2026-11-15 | 2026-10-23 |
| Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Sacituzumab govitecan, Atezolizumab, Durvalumab - Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Recruiting | Bindu R Potugari | 35 | 2026-05-14 | 2026-07-28 |
| Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC Albumin-bound Paclitaxel Combined with Local Therapy, Albumin-Bound Paclitaxel /nab-Paclitaxel - Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 84 | 2026-04-06 | 2026-04-23 |
| Iadademstat + SBRT With Atezo in ES-SCLC Iadademstat, Atezolizumab, SBRT - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 | Recruiting | Yale University | 15 | 2026-01-20 | 2026-09-14 |
| Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer Tislelizumab Combined With Chemotherapy - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Recruiting | Chongqing University Cancer Hospital | 36 | 2025-10-10 | 2026-02-23 |
| Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer HS-20093 in combination with Adebrelimab - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 | Not yet recruiting | Shanghai Hansoh Biomedical Co., Ltd | 50 | 2025-07-31 | 2025-07-14 |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only) - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 3 | Recruiting | Gilead Sciences | 695 | 2025-04-04 | 2026-10-20 |
| Second-line Immunotherapy for ES-SCLC Adebrelimab, Selinexor, Nab-paclitaxel - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Not applicable | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2025-02-28 | 2025-03-03 |
| Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). Atezolizumab, Carboplatin, Etoposide - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Recruiting | Gruppo Oncologico Italiano di Ricerca Clinica | 142 | 2025-01-24 | 2025-03-13 |
| ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer HS-20093 - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Withdrawn | Hansoh BioMedical R&D Company | 2024-11-30 | 2024-03-04 | |
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors IDE-161, Pembrolizumab - Advanced or Metastatic Solid Tumors, Breast Cancer | Phase 1 | Active not recruiting | IDEAYA Biosciences | 216 | 2023-04-18 | 2026-07-13 |
Small Cell Lung Carcinoma (4) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Recurrence (1)
Neoplasms (5) · Neoplasms by Site (5) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Lung Neoplasms (3) · Adnexal Diseases (1) · Breast Diseases (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Disease Attributes (1)
atezolizumab (3) · 130-nm albumin-bound paclitaxel (2) · sacituzumab govitecan (2) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Drug Therapy (1) · Etoposide (1) · Injections (1) · PM 01183 (1) · Topotecan (1) · amrubicin (1) · durvalumab (1) · iadademstat (1) · pembrolizumab (1) · selinexor (1)
Hansoh BioMedical R&D Company (2) · Bindu R Potugari (1) · Chongqing University Cancer Hospital (1) · Gilead Sciences (1) · Gruppo Oncologico Italiano di Ricerca Clinica (1) · IDEAYA Biosciences (1) · Shanghai Hansoh Biomedical Co., Ltd (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Yale University (1)
United States (4) · China (3) · Italy (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1) · Japan (1) · Malaysia (1)
Annie Chiang, MD (1) · Darrin Beaupre, MD,PhD (1)